SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with knife is capturing significant community attention through its multichain presence and unique deflationary burn mechanism. Supporters are actively driving a cult-like narrative, encouraging others to increase their holdings and framing the project as a standout meme coin with long-term potential.

Assertio Holdings, Inc. is a commercial pharmaceutical company, which engages in acquisitions, licensing, and mergers. The firm focuses on portfolio of neurology, inflammation, and pain medications. Its products include INDOCIN, Sympazan, Otrexup, SPRIX, CAMBIA, and Zipsor. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Holdings Inc

Assertio Holdings is trending as shareholders voice intense dissatisfaction with the company's $18-per-share sale to Garda Therapeutics, arguing the price significantly undervalues their core growth assets. Investors are actively debating the lack of transparency in the strategic review process, the removal of potential long-term upside in Rolvedon and Sympazan, and the perceived conflict of interest regarding executive compensation.

Asteroid Shiba is inspired by a real-life event where a Shiba Inu plush toy named "Asteroid" served as a zero-gravity indicator during the Polaris Dawn mission. This connection to space travel gives it a narrative that's both whimsical and grounded in a tangible event, differentiating it from other meme coins which might rely solely on internet culture or celebrity endorsements.  The coin's mascot, the zero-gravity Shiba Inu, was designed by a young cancer survivor, Liv Perrotto, adding a layer of emotional connection and human interest story that's rare in the crypto space. This backstory not only provides a unique selling point but also a community rallying point.

Asteroid Shiba

Asteroid Shiba is generating intense social media hype as traders debate whether its rapid price volatility signals a sustainable breakout or a speculative bubble. The community is actively comparing it to past viral token surges while speculating on potential high-profile endorsements and its role in a broader shift toward community-takeover crypto projects.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can&nbsp;earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

AAVE is trending as investors weigh its long-term potential in the decentralized finance sector, with many discussing its fundamental value, tokenomics, and recent protocol upgrades. While some community members remain focused on long-term accumulation and the potential for a larger breakout, others are debating the impact of ongoing market volatility and the competitive landscape of lending protocols.

BtcUSD is a completely decentralized stablecoin issued and managed by BTCFi, a platform where users can deposit Bitcoin of various formats to use as collaterals. BtcUSD offers Bitcoin holders the opportunity to generate additional yields with their Bitcoin positions through DeFi usage.

Bitcoin USD (BTCFi)

Bitcoin is currently locked in a consolidation phase near key resistance levels, with the community actively debating whether the asset will break through to establish new highs or undergo a deeper technical correction. Traders are heavily focused on critical support zones and the interplay between institutional ETF flows and broader market liquidity.

iShares Trust - iShares 0-3 Month Treasury Bond ETF

iShares 0-3 Month Treasury Bond ETF

Investors are increasingly turning to SGOV as a defensive parking spot for liquidity during periods of heightened market volatility and macroeconomic uncertainty. The community views the ETF as a stable hedge against potential downturns, frequently discussing it as a low-risk alternative to traditional cash accounts while waiting for more favorable entry points in equities.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigel Pharmaceuticals is currently a focal point for investors due to its strong commercial revenue growth and profitability in the oncology sector, alongside high expectations for upcoming Phase 1b clinical data for its R289 pipeline asset at the ASH conference. The community is actively discussing the stock's significant institutional ownership and high short interest, with many speculating on the potential for a short squeeze or a strategic acquisition by a larger pharmaceutical company.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors gear up for the upcoming BlueBird 7 launch on the New Glenn rocket, viewing the event as a critical milestone for validating the company's commercial network capabilities. The community is actively debating the significance of the launch while navigating recent volatility and news of institutional share sales, with many shareholders maintaining a bullish outlook on the company's long-term potential for global cellular connectivity.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a focal point for the crypto community, driven by excitement over its high-speed blockchain capabilities, growing DeFi and memecoin ecosystems, and anticipation surrounding potential ETF inflows. While some community members remain wary of volatility and ongoing market fluctuations, bulls are actively focused on staking and dip-buying as they eye long-term adoption trends within the Solana network.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is experiencing heightened investor frustration and debate, primarily driven by concerns over ongoing token dilution, stagnant price action relative to broader market gains, and leadership sentiment. While some community members remain aggressively bullish on long-term accumulation and the potential impact of proposed ETFs, others are pivoting toward emerging meme coins on the Cronos chain or exiting entirely, citing a lack of confidence in the platform's strategic direction.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mid Cap Stocks To Add to Your Watchlist - April 18th

ProShares UltraPro Short QQQ, Direxion Daily TSLA Bull 2X Shares, and Hims & Hers Health are the three Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are...

Top Healthcare Stocks To Follow Now - April 18th

UnitedHealth Group, Johnson & Johnson, and Hims & Hers Health are the three Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of companies involved in medical goods and servicesincluding pharmaceutical and biotechnology firms, medical dev...

Hims & Hers Health, Inc. (NYSE:HIMS) Sees Large Drop in Short Interest

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totaling 71,359,926...

Top Mid Cap Stocks To Add to Your Watchlist - April 17th

Top Medical Stocks To Watch Now - April 17th

Eli Lilly and Company, UnitedHealth Group, and Hims & Hers Health are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of companies...

Healthcare Stocks To Follow Now - April 17th

UnitedHealth Group, Hims & Hers Health, Johnson & Johnson, Intuitive Surgical, and Medtronic are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare...

Hims & Hers Health (HIMS) Soars 11.1%: Is Further Upside Left in the Stock?

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

<ul class="summary-bullets"><li>The 10-day ceasefire between Israel and Lebanon has gone into effect, while President Donald Trump struck an optimistic tone on the resolution with Iran.</li><li>Markets are beginning to price in de-escalation in the Middle East, sending crude below $100 and nudging equities higher.</li><li>Netflix slumped on weak guidance, while Nvidia remains under scrutiny amid rising skepticism despite its AI leadership.</li></ul>U.S. stock futures&nbsp;rose early Friday as investors weighed the likelihood of a resolution to the Middle East crisis. A 10-day ceasefire is in effect between Israel and Lebanon.&nbsp;Meanwhile, President Donald Trump on Thursday stated the war in Iran “should be ending pretty soon” and described negotiations as “going along swimmingly,” to reopen the Strait of Hormuz. Both countries are expected to resume peace talks over the weekend. Crude oil prices fell below $100/barrel on easing geopolitical tensions, while defense-linked companies found favor among investors.As of 4:00 a.m. ET on Friday, Dow futures rose 0.3%, S&amp;P 500 futures gained 0.1%, Nasdaq futures were flat, and Russell 2000 futures were up 0.2%.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has flipped to ‘extremely bullish,’ a sharp move from the ‘bearish’ sentiment earlier this week.&nbsp;Trending Stocks To WatchNetflix (NFLX):&nbsp;Shares fell nearly 10% in early pre-market trade following a disappointing forecast and the news that co-founder Reed Hastings will exit the board in June. However, CEO Ted Sarandos highlighted that the company’s cash position remains elevated following the failed bid for Warner Bros.&nbsp;Psyence Biomedical (PBM):&nbsp;The stock is attracting heavy retail attention on reports that the White House is preparing an executive order to support further federal research into the psychedelic compound ibogaine.WeShop Holdings (WSHP):&nbsp;The stock has nearly quadrupled in value over the past five sessions and is on track to log its best&nbsp;weekly performance since late November. Retail interest is surging ahead of its results, which are due later this month.&nbsp;Nvidia (NVDA):&nbsp;The AI giant remained under scrutiny after ‘The Big Short’ investor Michael Burry criticized CEO Jensen Huang’s recent podcast appearance. Burry claimed that Huang ‘squirmed and obfuscated’ when questioned about the company’s long-term moat and geopolitical risks.Hims &amp; Hers Health (HIMS):&nbsp;Shares have been gaining attention this week, with new signals from the U.S. Food and Drug Administration (FDA) suggesting that its testosterone therapy could be the next growth driver for this telehealth firm.Defense IPO Watch:&nbsp;Drone maker AEVEX (AVEX) raised $320 million in its IPO, pricing at $20 per share, and is set to debut on the NYSE today. Meanwhile, Arxis (ARXS) soared 36% in its Nasdaq debut on Thursday.AST SpaceMobile (ASTS)&nbsp;has confirmed the BlueBird 7 launch for Sunday, April 19.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Verizon (VZ), Iren Limited (IREN), Sidus Space (SIDU), and Rumble Inc (RUM).&nbsp;Other Catalysts To WatchOn the economic front, no notable data release is expected. Traders will be watching commentary from a host of Fed speakers throughout the day, including Richmond Fed President Tom Barkin and Fed Governor Christopher Waller.&nbsp;On earnings radar, watch out for quarterly reports from&nbsp;Fifth Third Bancorp (FITB), State Street (STT), Regions Financial (RF), Ally Financial (ALLY), Truist (TFC), and reAlpha Tech Corp (AIRE), among others, today.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Rise With ‘War Trade’ Unwinding: Why NFLX, WSHP, PBM, HIMS, NVDA Are Keeping Traders Engaged Today

Data from Stocktwits shows that retail positioning has shifted decisively from bearish sentiment earlier this week for SPY and QQQ. 

Equity

Data from Stocktwits shows that retail positioning has shifted decisively from bearish sentiment earlier this week for SPY and QQQ. 


<ul class="summary-bullets"><li>The FDA signaled openness to expanding testosterone therapy use for low libido linked to idiopathic hypogonadism, a condition without a known cause.</li><li>Hims began building its testosterone-care platform in September 2025, allowing providers to prescribe enclomiphene-based treatment and combination therapy.</li><li>BofA turned bullish on Hims, citing potential upside from upcoming July FDA advisory committee meetings reviewing peptide substances for inclusion on the 503A Bulks List.</li></ul>Shares of Hims &amp; Hers Health, Inc. (HIMS) have been riding a strong rally on peptide and weight-loss treatment momentum, but a fresh signal from the U.S. Food and Drug Administration (FDA) suggests the telehealth firm’s testosterone therapy could be emerging as the company’s next major growth pillar.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> jumped over 11% on Thursday, logging its fourth straight session of gains. Shares are headed&nbsp;for their best week in over a month.<h2 class="st-heading-2">FDA Opens Door To Broader Testosterone Therapy Use</h2>The FDA said on Thursday that it is encouraging sponsors of approved testosterone replacement therapy (TRT) products to contact the agency if they are interested in pursuing a potential new indication for treating low libido in men with idiopathic hypogonadism, a form of low testosterone without a known cause.&nbsp;The agency said the development follows a preliminary review of published clinical literature and a discussion at a December 2025 expert panel meeting, which identified evidence suggesting TRT may be safe and effective for certain men in this population.&nbsp;However, sponsors would still need to submit “substantial evidence” of clinical data showing that the benefits outweigh risks, and the FDA has asked interested companies to initiate discussions by April 30.Currently, FDA-approved TRT therapies are indicated only for men with hypogonadism linked to identifiable medical causes. TRT is used to restore hormone levels in men with low testosterone, a condition that can affect energy, mood, libido, bone density, and muscle strength, and is typically delivered through injections, gels, patches, or oral formulations.<h2 class="st-heading-2">Hims’ Testosterone Care Push&nbsp;</h2>Hims said in September 2025 that providers on its platform can prescribe personalized doses of compounded enclomiphene, a treatment that helps the body restore natural testosterone levels without affecting fertility. For men experiencing sexual-health symptoms linked to low testosterone, the company also introduced combination treatment options that pair enclomiphene with tadalafil, a commonly used erectile dysfunction medication.The company had also announced plans to expand further into testosterone care this year through exclusive access to the approved oral testosterone therapy Kyzatrex under a partnership with Marius Pharmaceuticals, with injectable testosterone options expected to follow.<h2 class="st-heading-2">Wall Street Flags Peptide Policy Tailwind</h2>The testosterone catalyst is emerging alongside regulatory developments in peptide access, which analysts say could drive additional growth opportunities for the company’s platform.Bank of America Securities (BofA) recently raised its price target on Hims &amp; Hers, citing potential upside from upcoming FDA advisory committee meetings in July that will review peptide substances for possible inclusion on the federal 503A Bulks List. A favorable outcome could allow the company to repurpose its existing GLP-1 infrastructure for additional peptide therapies as it transitions to branded weight-loss medicines, BofA said.&nbsp;Separately, Leerink called the recent regulatory progress around peptide access a “clear positive” for Hims &amp; Hers, saying any easing of restrictions could help “fill the growth hole” expected as the company shifts away from compounded obesity treatments. The brokerage added that a favorable advisory committee recommendation could allow Hims &amp; Hers to leverage its existing peptide facility.<h2 class="st-heading-2">How Do Retail Traders Feel About HIMS?</h2>On Stocktwits, retail sentiment was ‘extremely bullish’ amid nearly a 700% surge in message volumes over the past week.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_79debd59a3.webp" alt="hims ss.png" width="968" height="139"><figcaption>HIMS sentiment and message volume as of April 17 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/c2rshi2r/message/650484205">said</a>, “Everyone is excited for a long run like previous ones to $70. Given the momentum, FDA peptide reschedule, Novo partnership, international market broadening, potential short squeeze and earnings in a month, it is going to be a hell of a rally. Huge upside potential !!”<stembedurl>https://stocktwits.com/c2rshi2r/message/650484205</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Valueiskey/message/650538005">said</a>, “Tons of upside left here…too much good news and more possible revenue for HIMS.”<stembedurl>https://stocktwits.com/Valueiskey/message/650538005</stembedurl>HIMS stock has just turned positive for the year and is now up about 0.2%.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-lcid-abt-asbp-stocks-hit-52-week-lows-today/cZJUhKPRIxB">&nbsp;LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff?</a>

In this photo illustration, the logo of Hims & Hers Health, Inc. is displayed on a smartphone screen on May 04, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock's Rally May Have Plenty Of Room Left: FDA Opens Door To Testosterone Therapy 

Hims said last year that it plans to offer exclusive access to oral testosterone therapy Kyzatrex, with injectable options expected to follow.

Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies

Hims & Hers Health (NYSE:HIMS), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The stock moved higher as investors reacted to the FDA's decision to review compounded peptide therapies. T...

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

Hims & Hers Health Inc

Retail investors are betting on a massive short squeeze as the high short interest clashes with intense buying momentum.

The expanding peptide market is being viewed as the next major growth engine, potentially far surpassing existing GLP-1 revenue streams.

Traders are closely monitoring the critical $30 psychological resistance level, with many expecting an explosive move higher once breached.

Anticipated regulatory shifts, including potential eased restrictions on testosterone and other treatments, are fueling long-term investor optimism.

Fans argue the platform's vertical integration creates a massive competitive advantage that the broader market has significantly underestimated.

Current Price	$28.82
Prev Close	$26.99
Open	$27.67
Dividend Yield	0.00%
50-Day Moving Average	$19.93
Beta	2.22
Avg. Volume	44.55M
PE Ratio	55.20

52-Week High	$70.43
52-Week Low	$13.74
Market Capitalization	$6.57B
EPS (Annual)	$0.5123
Price to Book	12.11
Revenue Per Employee	$961,358.31

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HIMS News

HIMSHims & Hers Health Inc